HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence for drug design, announced today that it has secured the #1 global ranking for new U.S.

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.

In the latest bunch of recommendations from the European Medicines | Sanofi, Novo Nordisk, UCB and others received positive ...

Validfor is excited to announce the launch of its Agentic Digital Validation Platform for life sciences, designed to ...

The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe must meet exacting standards for dosage, purity, and sterility. This ...

Algorithms, markets, supply chains and national security systems make real-time decisions based on data as their primary input. Enterprise valuations rest on the integrity and reliability of their ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

The proposed platform is intended to enhance data-driven decision-making across Medicus’ clinical pipeline by integrating Reliant’s proprietary AI technology with Medicus’ clinical, operational, and ...

OKYO Pharma Limited Sponsored ADR ( (OKYO)) just unveiled an announcement. On December 19, 2025, OKYO Pharma marked its progress in developing treatments for neuropathic corneal pain by having ...

NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target ...